**NSE SME: QUESTALL** Quest Laboratories Limited is a technology-driven pharmaceutical manufacturer specializing in a comprehensive spectrum of formulations across **ethical, generic, and over-the-counter (OTC)** categories. Operating from its strategic hub in **Pithampur, Madhya Pradesh**, the company is currently undergoing a transformative shift from a domestic tender-based model to a high-margin, export-oriented global player. --- ### **Core Manufacturing Infrastructure & Product Portfolio** Quest Laboratories operates a **4,065 square meter** state-of-the-art facility equipped for diverse dosage forms. The company maintains **100% in-house quality control** and product stability laboratories, ensuring compliance with **ISO 9001:2015, GMP, GLP,** and **MSME Zed Bronze** standards. **Current Production Capacities:** | Product Form | Daily Production Capacity / Metric | | :--- | :--- | | **Tablets** | **0.9 Crore+** units | | **Capsules** | **0.1 Crore+** units | | **Syrups / Dry Suspensions** | **30,000+** units | | **Suspensions** | **25,000+** units | | **External Preparations** | **2,000+ Liters** | | **Ointments** | **1,000+ Kg** | **Portfolio Depth:** * **Licensed Formulations:** **1,300+** * **Active Products in Market:** **394+** * **Therapeutic Reach:** Antibiotics, Antimalarials, Antispasmodics, Anti-inflammatories, Antiemetics, Respiratory, Diabetes, Antidepressants, Antiallergics, and Cardiovascular drugs. --- ### **Strategic Growth Verticals & Capex Expansion** The company is executing a **₹30-35 crore capex plan** over three years to pivot toward high-value segments. A significant strategic shift involves sourcing machinery from **domestic suppliers** rather than China to align with "Made in India" initiatives and mitigate supply chain risks. * **Injectables & USFDA Compliance:** Construction is underway for a **USFDA-compliant injectable facility**. This plant will feature specialized lines for **Oncology, Ampoules, Vials, and Dry Injections**, targeting both domestic and regulated export markets. * **Capsule Production:** A new production line (capacity: **10 lakh units/day**) is expected to contribute **₹10–₹15 crore** in annual revenue starting in late **2025**. * **Oncology Plant:** The company acquired **44,000 sq. ft.** of land (Plot 44, Pithampur) in April 2025 specifically for dedicated oncology and injectable expansion. * **New Product Verticals:** Development is active for a new **Collagen** vertical (6 products) and **20+ cardiovascular and anti-diabetic drugs** currently under registration. --- ### **Global Market Penetration & Distribution Model** Quest Laboratories is aggressively diversifying its revenue streams to reduce dependency on government tenders and increase export contributions from **10-15% to 50%** within two years. **Distribution Channels:** * **Government Model:** Participation in public sector tenders (historically the largest revenue contributor). * **PCD (Propaganda-cum-Distribution):** Region-wise franchise partners. * **Merchant Export & Direct Export:** Indirect and direct international supply. * **Institutional & Ethical:** Direct supply chains for domestic ethical products. **International Footprint:** * **Myanmar:** A primary growth driver with a **₹25 crore order book** and a 3-year MOU with TOPS Co. Ltd worth **USD 1.35 million**. * **Africa & SE Asia:** Active registrations and engagements in **Angola, Kenya, Nigeria, Mali, Niger, Burkina Faso, Benin, Togo, Eritrea, Oman, Cambodia, and Thailand**. --- ### **Financial Performance & Growth Metrics** The company has demonstrated robust financial health, characterized by high-growth compounding and a successful listing on the **NSE SME-Emerge Platform** in May 2024. **Historical Financial Growth (3-Year CAGR):** * **Revenue CAGR:** **20.4%** * **EBITDA CAGR:** **35.2%** * **PAT CAGR:** **48.9%** **Key Financial Data:** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue (₹ Cr)** | **108.21** | **82.79** | **61.87** | | **Profit After Tax (₹ Cr)** | **13.57** | **10.09** | **5.04** | | **EBITDA Margin Target** | **18-20%** | - | - | | **Return on Equity (ROE)** | **16.6%** | - | - | | **Return on Capital (ROCE)** | **12.1%** | - | - | --- ### **IPO Proceeds & Capital Allocation** The company raised **₹43.16 crore** via its IPO. In January 2025, shareholders approved a variation in the use of proceeds, redirecting funds from Chinese machinery to domestic procurement to accelerate the 12-month implementation timeline. | Object of Issue | Allocation (₹ Lakhs) | | :--- | :--- | | **Plant & Machinery Capex** | **2,600.00** | | **Working Capital** | **1,000.00** | | **General Corporate Purposes** | **337.99** | --- ### **Risk Management & Operational Sustainability** Quest Laboratories operates under a formal **Risk Management Policy** overseen by the Board and Audit Committee to navigate the highly regulated pharmaceutical landscape. * **Regulatory Compliance:** High entry barriers require continuous validation of safety and efficacy across varying international jurisdictions. * **Financial Risk Mitigation:** The company uses **foreign exchange forward contracts** to manage currency volatility and performs rigorous credit assessments of counterparties to limit default probability. * **Inventory Oversight:** Management has addressed auditor "Emphasis of Matter" regarding inventory valuation by strengthening physical verification processes. * **Sustainability:** The Pithampur site operates a **Rain Water Harvesting System**, maintains **zero emissions** from production, and participates in **carbon credit initiatives**. * **R&D Commitment:** The company allocates **2% of total revenue** to R&D to ensure a continuous pipeline of advanced formulations.